Medium pp

Polaris Pharmaceuticals

 
  • +1-858-452-6688
  • Networkers
  • United States of America

About Polaris Pharmaceuticals

Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group) is a biopharmaceutical company specializing in the research and development of novel treatments for cancer. Pegargiminase (ADI-PEG 20) is a potential first-in-class targeted cancer therapy in late-stage clinical development for a wide range of cancers, especially hepatocellular carcinoma and malignant pleural mesothelioma. Based in San Diego, California, USA, Polaris Pharmaceuticals collaborates with major pharmaceutical companies and more than 40 cancer centers worldwide. The multinational Polaris Group also includes high-quality in-house current good manufacturing practice (cGMP) manufacturing through wholly owned subsidiaries. Its global clinical trial program is supported by a highly experienced management team and renowned scientific advisors, including James Allison, who was awarded the 2018 Nobel Prize in Physiology or Medicine for his pioneering work on cancer immunotherapy.

Therapeutic Areas

Oncology

Technologies

Other

Company Type

Pharmaceutical

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

March 2019